Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00081926
Status:
COMPLETED
Last Update Posted:
2009-11-23
First Post:
2004-04-26
Brief Title:
Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2009-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the molecular response to high dose Gleevec in newly diagnosed patients with Chronic Myelogenous Leukemia CML in Chronic Phase This study will evaluate the ability of Gleevec to reduce the amount of abnormal protein that occurs in patients with CML
Patients who are eligible to participate will be treated for 18 months This trial will include male or female patients 18 years or older who are newly diagnosed within 6 months with CML
Patients who are eligible to participate will be treated for 18 months This trial will include male or female patients 18 years or older who are newly diagnosed within 6 months with CML
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| RIGHT Trial | None | None | None |
| US177 | None | None | None |